

# Burcin Ã–zdirik

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6647424/publications.pdf>

Version: 2024-02-01

17  
papers

181  
citations

1307594

7  
h-index

1125743

13  
g-index

17  
all docs

17  
docs citations

17  
times ranked

267  
citing authors

#	ARTICLE	IF	CITATIONS
1	Low Serum Levels of Soluble Receptor Activator of Nuclear Factor $\kappa$ B Ligand (sRANKL) Are Associated with Metabolic Dysregulation and Predict Long-Term Mortality in Critically Ill Patients. <i>Diagnostics</i> , 2022, 12, 62.	2.6	1
2	Soluble Urokinase Plasminogen Activator Receptor Levels Are Associated with Severity of Fibrosis in Patients with Primary Sclerosing Cholangitis. <i>Journal of Clinical Medicine</i> , 2022, 11, 2479.	2.4	2
3	Models of Gastroenteropancreatic Neuroendocrine Neoplasms: Current Status and Future Directions. <i>Neuroendocrinology</i> , 2021, 111, 217-236.	2.5	17
4	From Liver Cirrhosis to Cancer: The Role of Micro-RNAs in Hepatocarcinogenesis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1492.	4.1	16
5	Lessons From Immune Checkpoint Inhibitor Trials in Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 652172.	4.8	21
6	The Role of Microbiota in Primary Sclerosing Cholangitis and Related Biliary Malignancies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6975.	4.1	22
7	Atezolizumab and bevacizumab-induced encephalitis in advanced hepatocellular carcinoma. <i>Medicine (United States)</i> , 2021, 100, e26377.	1.0	10
8	The Role of miRNA in the Pathophysiology of Neuroendocrine Tumors. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8569.	4.1	8
9	PD-L1 inhibitors in neuroendocrine neoplasia. <i>Medicine (United States)</i> , 2021, 100, e23835.	1.0	7
10	In Vivo Models for Cholangiocarcinoma—What Can We Learn for Human Disease?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4993.	4.1	8
11	Analysis of miR-29 Serum Levels in Patients with Neuroendocrine Tumors—Results from an Exploratory Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 2881.	2.4	8
12	A case report of an excellent response to interferon- $\gamma$ in a patient with functional metastasized neuroendocrine tumor refractory to other treatments. <i>Medicine (United States)</i> , 2020, 99, e20820.	1.0	1
13	Soluble Urokinase Plasminogen Activator Receptor (suPAR) Concentrations Are Elevated in Patients with Neuroendocrine Malignancies. <i>Journal of Clinical Medicine</i> , 2020, 9, 1647.	2.4	6
14	Systemic treatment of hepatocellular carcinoma: from sorafenib to combination therapies. <i>Hepatic Oncology</i> , 2020, 7, HEP20.	4.2	30
15	Primary Neuroendocrine Neoplasms of the Breast: Case Series and Literature Review. <i>Cancers</i> , 2020, 12, 733.	3.7	17
16	Serum levels of miR-223 but not miR-21 are decreased in patients with neuroendocrine tumors. <i>PLoS ONE</i> , 2020, 15, e0244504.	2.5	3
17	A rare case of a patient with a high grade neuroendocrine tumor developing neutropenic sepsis after receiving PRRT combined with Capecitabine or Temozolomide: A case report. <i>Molecular and Clinical Oncology</i> , 2020, 14, 20.	1.0	4